IGM Biosciences (IGMS) Stifel 2024 Healthcare Conference summary

Strategic pivot and industry context

• Recently shifted focus exclusively to autoimmune diseases, moving away from oncology after evaluating emerging data and unmet criteria in oncology programs.

• Industry-wide trend observed as many companies, including large pharma partners, are prioritizing autoimmune disease development.

• The pendulum may swing back to oncology in the future, but current activity and investment are heavily concentrated in autoimmunity.

Imvotamab development and differentiation

• Imvotamab, an IgM-based T-cell engager, is being developed for RA, lupus, and myositis, aiming for deeper B-cell depletion than IgG-based therapies without CAR-T burdens.

• The molecule’s multivalent structure (10:1 CD20:CD3 binding) is designed for high avidity, low off-rate, and controlled T-cell activation, supporting a favorable safety profile.

• Safety and therapeutic index are seen as key differentiators, with the IgM format potentially offering advantages over existing IgG and CAR-T approaches.

Clinical progress and data strategy

• RA program is progressing as planned, with recent clearance of cohort three; lupus program is attracting significant interest despite strict inclusion criteria.

• Myositis study, in collaboration with Stanford, is smaller and translational, focusing on local disease biology through biopsies.

• Data update timeline was extended to mid-2025 to ensure a robust, multi-cohort dataset with sufficient follow-up, aiming to inform both future value and efficient phase II planning.